RxDoctor Payments Data

Alexander Morf, MD

Internal Medicine · Santa Barbara, CANPI 1932485281

Payments from drug & device makers

$9,126in general payments, 2019–2025

Across 473 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Pfizer$942
  • Johnson & Johnson$551
  • Boehringer Ingelheim$482
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$9,126100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,126 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$359,649
Medicare patients
662
Services billed
3,747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$85,006
JardianceEmpagliflozin52$68,954
MounjaroTirzepatide32$45,142
XareltoRivaroxaban26$32,759
OzempicSemaglutide25$31,012
MyrbetriqMirabegron26$13,792
TrulicityDulaglutide11$10,492
CreonLipase/Protease/Amylase15$9,427
ShingrixVaricella-Zoster Ge/As01b/Pf31$6,839
NamzaricMemantine Hcl/Donepezil Hcl12$6,703
VascepaIcosapent Ethyl18$6,545
LyricaPregabalin11$6,080
Atorvastatin Calcium556$5,855
Meprobamate11$4,899
DayvigoLemborexant13$4,586

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lyrica, Paxlovid$942$95,312142 claims
Boehringer IngelheimJardiance, Pradaxa$482$71,85566 claims
Lilly USA, LLCMounjaro, Trulicity$370$55,63443 claims
Johnson & JohnsonXarelto$551$32,75926 claims
Novo NordiskOzempic$1,012$31,01225 claims
AbbVieCreon, Namzaric, Synthroid$1,331$20,24985 claims
Astellas Pharma US IncMyrbetriq$188$13,79226 claims
GSKShingrix$252$6,83931 claims
Eisai Inc.Dayvigo$54$4,58613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →